Effector Therapeutics

OverviewSuggest Edit

Effector Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.

TypePrivate
Founded2012
HQSan Diego, USMap
Websiteeffector.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Sep 2019)34

Effector Therapeutics Office Locations

Effector Therapeutics has an office in San Diego
San Diego, US (HQ)
11180 Roselle St
Show all (1)

Effector Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2012

Effector Therapeutics total Funding

$101 m

Effector Therapeutics latest funding size

$16 m

Time since last funding

4 years ago

Effector Therapeutics investors

U.S. Venture Partners (USVP), Osage University Partners, SR One, Novartis Venture Fund, Altitude Life Science Ventures, Astellas Venture Management, Abingworth, The Column Group, Mission Bay Capital, AbbVie Biotech Ventures
Effector Therapeutics's latest funding round in February 2016 was reported to be $16 m. In total, Effector Therapeutics has raised $101 m
Show all financial metrics

Effector Therapeutics Online and Social Media Presence

Effector Therapeutics's Trends

Embed Graph

Effector Therapeutics Blogs

March 29, 2019

eFFECTOR Presents Data on its Selective Translation Regulators at AACR 2019 Annual Meeting

January 14, 2019

Research Published in Nature Medicine Demonstrates the Immunological Effects of Tomivosertib, Including Inhibiting Production of Checkpoint Protein PD-L1 and Increasing T Cell Infiltration into Tumors

SAN DIEGO, January 14, 2019 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced publication in the peer reviewed journal Nature Medicine of preclinical research demonstrating that tomivosertib (eFT508), th…
December 11, 2018

eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)

SAN DIEGO, CA — December 11, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it has dosed the first patient in a Phase 2 trial of tomivosertib (eFT508) in men with advanced castra…
December 03, 2018

Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer

SAN DIEGO, December 3, 2018 — eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced today that it presented data on Sunday, December 2 at the AACR Special Conference on PI3K/mTOR Signaling demonstrating …
October 16, 2018

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR’s Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer

SAN DIEGO, October 16, 2018 - eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada)
July 27, 2018

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

SAN DIEGO, July 27, 2018 -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company’s oral, small molecule in…
Show more

 Effector Therapeutics Frequently Asked Questions

  • When was Effector Therapeutics founded?

    Effector Therapeutics was founded in 2012.

  • How many employees does Effector Therapeutics have?

    Effector Therapeutics has 34 employees.

  • Who are Effector Therapeutics competitors?

    Competitors of Effector Therapeutics include Cleveland BioLabs, XBiotech and Aeglea Biotherapeutics.

  • Where is Effector Therapeutics headquarters?

    Effector Therapeutics headquarters is located at 11180 Roselle St, San Diego.

  • Where are Effector Therapeutics offices?

    Effector Therapeutics has an office in San Diego.

  • How many offices does Effector Therapeutics have?

    Effector Therapeutics has 1 office.